Analyst Ratings For Evgen Pharma PLC (LON:EVG)
Today, Northland Securities reiterated its Buy rating on Evgen Pharma PLC (LON:EVG).
There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Evgen Pharma PLC (LON:EVG) is Buy with a consensus target price of GBX 113 per share, a potential .
Some recent analyst ratings include
- 7/25/2018-Northland Securities Reiterated Rating of Buy.
- 6/11/2018-Northland Capital Partners Reiterated Rating of Buy.
- 12/15/2017-Beaufort Securities Reiterated Rating of Speculative Buy.
About Evgen Pharma PLC (LON:EVG)
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex for synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Recent Trading Activity for Evgen Pharma PLC (LON:EVG)
Shares of Evgen Pharma PLC closed the previous trading session at 17,50 −0,25 1,41 % with 5767 shares trading hands.
